Aptevo says mipletamig combo shows 81% remission in frontline AML trial cohort 5

Aptevo Therapeutics, Inc.

Aptevo Therapeutics, Inc.

APVO

0.00
  • Aptevo Therapeutics reported new interim results from RAINIER, its Phase 1b dose-optimization study of mipletamig with venetoclax, azacitidine in frontline acute myeloid leukemia, with Phase 2 dose selection targeted for 2026.
  • Across 31 evaluable patients through Cohort 5, responses and overall clinical benefit continued to compare favorably with historical outcomes for venetoclax with azacitidine alone.
  • Safety remained favorable in the expanding dataset, supporting continued dose escalation into final cohorts intended to complete dose selection package.
  • Trial remained on track to finish dose optimization in 2026, positioning program for planned Phase 2 regulatory interaction.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptevo Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202605060805ACCESSWRNAPR_____1164140) on May 06, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.